ABVC BioPharma (NASDAQ:ABVC) Trading 2.6% Higher – Here’s Why

ABVC BioPharma, Inc. (NASDAQ:ABVC) shot up 2.6% during mid-day trading on Monday . The company traded as high as $1.6129 and last traded at $1.57. Approximately 183,346 shares changed hands during trading, an increase of 38% from the average daily volume of 133,089 shares. The stock had previously closed at $1.53.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded shares of ABVC BioPharma from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, June 15th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, ABVC BioPharma has a consensus rating of “Sell”.

ABVC BioPharma Trading Up 2.6%

The business has a 50-day moving average price of $1.23 and a 200-day moving average price of $1.54. The stock has a market cap of $40.82 million, a PE ratio of -3.92 and a beta of 0.56.

ABVC BioPharma (NASDAQ:ABVC) last issued its quarterly earnings results on Monday, May 18th. The company reported ($0.06) EPS for the quarter.

Institutional Trading of ABVC BioPharma

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Geode Capital Management LLC raised its position in shares of ABVC BioPharma by 7.7% during the 4th quarter. Geode Capital Management LLC now owns 202,365 shares of the company’s stock worth $431,000 after purchasing an additional 14,553 shares during the last quarter. Millennium Management LLC acquired a new stake in ABVC BioPharma in the 3rd quarter worth about $60,000. Finally, Citadel Advisors LLC acquired a new stake in ABVC BioPharma in the 3rd quarter worth about $48,000. Hedge funds and other institutional investors own 11.38% of the company’s stock.

About ABVC BioPharma

ABVC BioPharma is a clinical-stage biotechnology company focused on the discovery and development of novel vaccine and immunotherapy candidates for oncology and infectious diseases. The company leverages a proprietary peptide-based platform to identify and synthesize immunogenic epitopes, aiming to stimulate targeted immune responses against tumor-associated and pathogen-derived antigens.

The company’s pipeline includes active immunotherapy programs designed to address a range of cancer indications, along with vaccine candidates targeting bacterial pathogens.